Prognostic importance of DNA-ploidy and S-phase fraction in endometrial cancer
On fresh frozen tumor tissue from 161 patients with endometrial cancer DNA-ploidy and S-phase fraction were measured in a prospective study to evaluate their prognostic and predictive value. All FIGO stage I or II patients had surgery and were included in an adjuvant trial comparing tamoxifen 30 mg...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 01, 1994
|
| In: |
International journal of gynecological cancer
Year: 1994, Volume: 4, Issue: 4, Pages: 250-256 |
| ISSN: | 1525-1438 |
| DOI: | 10.1046/j.1525-1438.1994.04040250.x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1046/j.1525-1438.1994.04040250.x Verlag, lizenzpflichtig, Volltext: https://ijgc.bmj.com/content/4/4/250 
|
| Author Notes: | G. von Minckwitz, W. Kühn, M. Kaufmann, G.E. Feichter, J. Heep, H. Schmid, G. Bastert |
| Summary: | On fresh frozen tumor tissue from 161 patients with endometrial cancer DNA-ploidy and S-phase fraction were measured in a prospective study to evaluate their prognostic and predictive value. All FIGO stage I or II patients had surgery and were included in an adjuvant trial comparing tamoxifen 30 mg p.o. versus medroxyprogesterone acetate 500 mg p.o. for 2 years versus no therapy. Diploid (DNA index (DI) ⩽ 1.1) tumors were found in 75%. S-phase fraction was elevated (>5%) in 46 (30%) of the patients. Significant correlations of DNA-ploidy and S-phase fraction were found with classical parameters such as stage, grade, histologic type and estrogen and progesterone receptor status. Patients with FIGO stage I aneuploid tumors showed significantly shorter disease-free interval (DFS) and overall survival (OAS). Recurrences and deaths occurred more often in tumors with raised S-phase fraction. In these early stages clinical outcome was worst if both factors were unfavorable. In multivariate analysis of stage I tumors DNA-ploidy and S-phase fraction were independent of grade, type and estrogen receptor status. Patients whose tumors had elevated S-phase fractions (>5%) gained more benefit from endocrine treatment than patients with low S-phase fractions. Patients with diploid and aneuploid tumors had prolonged DFS and improved OAS, if they had received adjuvant hormonal therapy. In endometrial cancer, DNA-ploidy and S-phase fraction are objective and reliable prognostic and predictive parameters which should be integrated into the clinical management. |
|---|---|
| Item Description: | Gesehen am 14.02.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1525-1438 |
| DOI: | 10.1046/j.1525-1438.1994.04040250.x |